Source - LSE Regulatory
RNS Number : 5883F
Ergomed plc
19 July 2021



Appointment of Joint Corporate Broker



Guildford, UK - 19 July 2021: Ergomed plc (LSE: ERGO) ('Ergomed' or the 'Company'), a company focused on providing specialised services to the pharmaceutical industry, announces the appointment of Peel Hunt as the Group's joint corporate broker with immediate effect. Numis will continue to act as the Group's Nominated Adviser and joint corporate broker.






Ergomed plc                                                                              Tel: +44 (0) 1483 402 975

Miroslav Reljanović (Executive Chairman)          

Richard Barfield (Chief Financial Officer)           


Numis Securities Limited                                                         Tel: +44 (0) 20 7260 1000

Freddie Barnfield / Matthew O'Dowd (Nominated Adviser)          

James Black (Broker)   


Peel Hunt LLP                                                                            Tel: +44 (0) 20 7418 8900

James Steel / Dr. Christopher Golden


Consilium Strategic Communications                                    Tel: +44 (0) 20 3709 5700

Chris Gardner / Matthew Neal                                           

Angela Gray




About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand and a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO). For further information, visit:


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.